Intermittent androgen deprivation.
Intermittent androgen deprivation is a controversial approach to management of prostate cancer. Preclinical models have demonstrated delay in time to prostate-specific antigen (PSA) progression in athymic mice bearing LNCaP tumors and a delay in time to androgen independence in androgen-dependent Shionogi carcinoma tumors in castrated animals exposed to intermittent androgen. Phase II clinical trials have demonstrated improved sexual function and quality of life in men discontinuing androgen deprivation. The average percentage of time spent off androgen deprivation ranges from 37% to 58%. Most men respond to retreatment with hormonal therapy. Current ongoing phase III clinical trials of intermittent versus continuous androgen deprivation in men with metastatic disease or recurrent disease after localized therapy will assess the comparative impact on quality of life and survival. Final analyses of these critical trials will define the ultimate role of this approach in prostate cancer. In the interim, intermittent androgen deprivation should be considered an experimental approach.
Dawson
N A
NA
Division of Hematology/Oncology, University of Maryland Greenebaum Cancer Center, 22 South Greene Street, Baltimore, MD 21201-1595, USA. ndawson@umgcc.umaryland.edu
D000726:Androgen Antagonists / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D017209:Apoptosis; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D018450:Disease Progression; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D051379:Mice; D008819:Mice, Nude; D017430:Prostate-Specific Antigen / Q000032:analysis; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011788:Quality of Life; D019529:Sexuality
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D017430:Prostate-Specific Antigen